Australia's most trusted
source of pharma news
Monday, 02 February 2026
Posted 29 July 2024 AM
Just days ahead of losing exclusivity for Stelara in Australia, Johnson & Johnson registered the $397 million blockbuster under the new brand name Setrelvo.
Stelara officially lost patent protection in Australia yesterday (Sunday) with Amgen primed to launch its own versions of the drug.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.